Informed consent for a prescription drug

Impact of disclosed information on patient understanding and medical outcomes

Kimberly A. Quaid, Ruth R. Faden, Eileen P. Vining, John M. Freeman

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Based on the two legal standards of informed consent currently in use, the Medical Practice Standard and the Reasonable Person Standard, two disclosures containing information about the risks and benefits of the anticonvulsant, Carbamazepine, were empirically derived. One of these two disclosures was randomly given to a sample of 39 seizure patients and the parents of pediatric seizure patients prescribed this drug. Subjects were interviewed either immediately after disclosure and at followup, or at followup only. The results provide no evidence for the hypothesized negative effects - anxiety, treatment refusal, reduced compliance and increased side effects - of providing patients with extensive disclosures about prescription drugs.

Original languageEnglish (US)
Pages (from-to)249-259
Number of pages11
JournalPatient Education and Counseling
Volume15
Issue number3
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Prescription Drugs
Disclosure
Informed Consent
Seizures
Treatment Refusal
Carbamazepine
Anticonvulsants
Compliance
Anxiety
Parents
Pediatrics
Pharmaceutical Preparations

Keywords

  • Informed consent
  • Medical ethics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Informed consent for a prescription drug : Impact of disclosed information on patient understanding and medical outcomes. / Quaid, Kimberly A.; Faden, Ruth R.; Vining, Eileen P.; Freeman, John M.

In: Patient Education and Counseling, Vol. 15, No. 3, 1990, p. 249-259.

Research output: Contribution to journalArticle

Quaid, Kimberly A. ; Faden, Ruth R. ; Vining, Eileen P. ; Freeman, John M. / Informed consent for a prescription drug : Impact of disclosed information on patient understanding and medical outcomes. In: Patient Education and Counseling. 1990 ; Vol. 15, No. 3. pp. 249-259.
@article{aa9e3312b7e74ff7ade36b018ac56815,
title = "Informed consent for a prescription drug: Impact of disclosed information on patient understanding and medical outcomes",
abstract = "Based on the two legal standards of informed consent currently in use, the Medical Practice Standard and the Reasonable Person Standard, two disclosures containing information about the risks and benefits of the anticonvulsant, Carbamazepine, were empirically derived. One of these two disclosures was randomly given to a sample of 39 seizure patients and the parents of pediatric seizure patients prescribed this drug. Subjects were interviewed either immediately after disclosure and at followup, or at followup only. The results provide no evidence for the hypothesized negative effects - anxiety, treatment refusal, reduced compliance and increased side effects - of providing patients with extensive disclosures about prescription drugs.",
keywords = "Informed consent, Medical ethics",
author = "Quaid, {Kimberly A.} and Faden, {Ruth R.} and Vining, {Eileen P.} and Freeman, {John M.}",
year = "1990",
doi = "10.1016/0738-3991(90)90100-Y",
language = "English (US)",
volume = "15",
pages = "249--259",
journal = "Patient Education and Counseling",
issn = "0738-3991",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Informed consent for a prescription drug

T2 - Impact of disclosed information on patient understanding and medical outcomes

AU - Quaid, Kimberly A.

AU - Faden, Ruth R.

AU - Vining, Eileen P.

AU - Freeman, John M.

PY - 1990

Y1 - 1990

N2 - Based on the two legal standards of informed consent currently in use, the Medical Practice Standard and the Reasonable Person Standard, two disclosures containing information about the risks and benefits of the anticonvulsant, Carbamazepine, were empirically derived. One of these two disclosures was randomly given to a sample of 39 seizure patients and the parents of pediatric seizure patients prescribed this drug. Subjects were interviewed either immediately after disclosure and at followup, or at followup only. The results provide no evidence for the hypothesized negative effects - anxiety, treatment refusal, reduced compliance and increased side effects - of providing patients with extensive disclosures about prescription drugs.

AB - Based on the two legal standards of informed consent currently in use, the Medical Practice Standard and the Reasonable Person Standard, two disclosures containing information about the risks and benefits of the anticonvulsant, Carbamazepine, were empirically derived. One of these two disclosures was randomly given to a sample of 39 seizure patients and the parents of pediatric seizure patients prescribed this drug. Subjects were interviewed either immediately after disclosure and at followup, or at followup only. The results provide no evidence for the hypothesized negative effects - anxiety, treatment refusal, reduced compliance and increased side effects - of providing patients with extensive disclosures about prescription drugs.

KW - Informed consent

KW - Medical ethics

UR - http://www.scopus.com/inward/record.url?scp=0025375930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025375930&partnerID=8YFLogxK

U2 - 10.1016/0738-3991(90)90100-Y

DO - 10.1016/0738-3991(90)90100-Y

M3 - Article

VL - 15

SP - 249

EP - 259

JO - Patient Education and Counseling

JF - Patient Education and Counseling

SN - 0738-3991

IS - 3

ER -